

Human TruStain FcX™ (Fc Receptor Blocking Solution)

Catalog# / Size	422301 / 50 tests 422302 / 200 tests
Regulatory Status	RUO
Other Names	Fc Blocker, FcγR blocker, Fc inhibitor
Description	Human Fc receptors (FcRs) are expressed on a variety of cells, such as monocytes, granulocytes, B cells and dendritic cells. The cells with FcR expression sometimes give false positive or false negative results of immunofluorescent staining due to the FcRs-mediated Ig Fc binding. Human TruStain FcX™ is specially formulated for blocking the FcR-involved unwanted staining without interfering with antibody-mediated specific staining of human cells. Human TruStain FcX™ is compatible with flow cytometric staining with anti-human CD16 (clone 3G8), CD32 (clone FUN-2), and CD64 (clone 10.1) antibodies.

Product Details

Storage & Handling	Store between 2°C and 8°C.
Application	FC - Quality tested ICFC, ICC - Reported in the literature, not verified in house
Recommended Usage	It is recommended to add 5 µl of Human TruStain FcX™ per million cells in 100 µl staining volume, mix and incubate at room temperature for 5-10 minutes prior to staining with antibody of interest. It is not necessary to wash cells between these blocking and immunostaining steps.
Application Notes	This buffer contains specialized human IgG in PBS containing 0.09% sodium azide. It is not recommended to be used for staining human IgG. Handle as biohazard agent.
Application References	<ol style="list-style-type: none"> de la Cruz J, <i>et al.</i> 2011. <i>J. Immunol.</i> 186:2282. PubMed Luo L, <i>et al.</i> 2011. <i>Exp Mol Pathol.</i> 91:596. PubMed Szerlip NJ, <i>et al.</i> 2012. <i>PNAS.</i> 109:3041. PubMed Bromley SK, <i>et al.</i> 2013. <i>J. Immunol.</i> 190:970. PubMed Trujillo G, <i>et al.</i> 2013. <i>J. Immunol.</i> 191:848. PubMed Edin S, <i>et al.</i> 2013. <i>PLoS One.</i> 18:74982. PubMed Euzebio Alves VT, <i>et al.</i> 2013. <i>Infect Immun.</i> 81:4399. PubMed Borg ZD, <i>et al.</i> 2014. <i>J. Immunol.</i> 192:189. PubMed Klingenberg R, <i>et al.</i> 2014. <i>Eur Heart J.</i> PubMed Lines JL, <i>et al.</i> 2014. <i>Cancer Res.</i> 74:1924. PubMed Decker D, <i>et al.</i> 2014. <i>Lupus.</i> 23:802. PubMed Jitschin R, <i>et al.</i> 2014. <i>Blood.</i> 123:2663. PubMed Anderson ME Jr, <i>et al.</i> 2014. <i>Otolaryngol Head Neck Surg.</i> 150:880. PubMed Giurisato E, <i>et al.</i> 2014. <i>Mol Biol Cell.</i> 25:1769. PubMed Shi J, <i>et al.</i> 2014. <i>Blood.</i> 123:4015. PubMed Kusner LL, <i>et al.</i> 2014. <i>PLoS One.</i> 9:102231. PubMed Fujisawa D, <i>et al.</i> 2014. <i>J Allergy Clin Immunol.</i> 134:622. PubMed Bhardwaj N, <i>et al.</i> 2014. <i>J Virol.</i> 88:11108. PubMed Lieber S, <i>et al.</i> 2014. <i>Mol Pharmacol.</i> 87:162. PubMed Olagnier D, <i>et al.</i> 2014. <i>PLoS Pathog.</i> 10:1004566. PubMed Punyadee N, <i>et al.</i> 2015. <i>J Virol.</i> 89:1587. PubMed Vuong TT, <i>et al.</i> 2015. <i>J Histochem Cytochem.</i> 63:280. PubMed Klingenberg R, <i>et al.</i> 2015. <i>Eur Heart J.</i> 36:1041. PubMed Wilkinson-Ryan I, <i>et al.</i> 2015. <i>PLoS One.</i> 10:125851. PubMed

Product Citations

- Argüello RJ, *et al.* 2020. *Cell Metab.* 32:1063. [PubMed](#)
- Aguilar EG, *et al.* 2021. *Blood Adv.* 5:4219. [PubMed](#)
- Lambert E, *et al.* 2022. *Acta Neuropathol Commun.* 10:4. [PubMed](#)
- Tocheva AS, *et al.* 2020. *Curr Protoc Immunol.* 130:e103. [PubMed](#)
- Ptacin JL, *et al.* 2021. *Nat Commun.* 12:4785. [PubMed](#)
- Lau D, *et al.* 2022. *Nat Commun.* 13:4053. [PubMed](#)
- Sipe CJ, *et al.* 2022. *Int J Mol Sci.* 23: [PubMed](#)
- Alber S, *et al.* 2022. *Front Immunol.* 13:838636. [PubMed](#)
- Klingenberg R, *et al.* 2014. *Eur Heart J.* [PubMed](#)

10. Fujisawa D, *et al.* 2014. J Allergy Clin Immunol. 134:622. [PubMed](#)
 11. Simon A, *et al.* 2015. Blood. 126: 378 - 385. [PubMed](#)
 12. Mitton B, *et al.* 2016. Leukemia. 10.1038/leu.2016.139. [PubMed](#)

RRID AB_2818986 (BioLegend Cat. No. 422302)


Antigen Details

Molecular Family Fc Receptors
Gene ID NA


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Product Data



Human TruStain FcX™ treated (blue) or non-treated (red) THP-1 cells stained with an irrelevant mouse IgG2a PE mAb (above). Dotted histogram represents unstained cells.



Human TruStain FcX™ treated (blue) or non-treated (red) THP-1 cells stained with an irrelevant rat IgG2b PE mAb (above). Dotted histogram represents unstained cells.



Human TruStain FcX™ treated (filled histograms) or non-treated (open histograms) THP-1 cells stained with anti-human HLA-DR PE (red) or an isotype control (IgG2a PE, blue) mAbs. Note: non-treated cells show false-negative HLA-DR staining due to high binding of mouse IgG2a isotype.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally

similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587